Mizuho Forecasts Strong Price Appreciation for DexCom (NASDAQ:DXCM) Stock

DexCom (NASDAQ:DXCM) had its price target boosted by equities research analysts at Mizuho from $78.00 to $90.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical device company’s stock. Mizuho’s price objective would suggest a potential upside of 38.29% from the company’s previous close.

Several other brokerages also recently issued reports on DXCM. Sanford C. Bernstein restated an “outperform” rating and set a $86.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, January 9th. Evercore initiated coverage on DexCom in a report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price target for the company. Royal Bank Of Canada reduced their price target on DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Finally, Canaccord Genuity Group set a $99.00 target price on DexCom and gave the stock a “buy” rating in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $85.59.

DexCom Trading Down 4.5%

DXCM stock opened at $65.08 on Friday. DexCom has a one year low of $54.11 and a one year high of $93.25. The stock has a market cap of $25.38 billion, a price-to-earnings ratio of 36.16, a price-to-earnings-growth ratio of 1.22 and a beta of 1.49. The company has a fifty day moving average price of $68.94 and a two-hundred day moving average price of $69.88. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.45 EPS. Equities analysts anticipate that DexCom will post 2.03 EPS for the current year.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC boosted its position in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares in the last quarter. Empowered Funds LLC increased its stake in DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares during the last quarter. Focus Partners Wealth increased its stake in DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares during the last quarter. Finally, Inspire Investing LLC acquired a new position in DexCom during the second quarter valued at approximately $258,000. Institutional investors own 97.75% of the company’s stock.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat consensus: DXCM reported $0.68 EPS vs. $0.65 expected and revenue of $1.26B (up ~13% YoY), showing continued top-line growth and margin improvement that likely drove buyer interest. Dexcom beats quarterly estimates on strong demand for glucose monitors
• Positive Sentiment: Company press release and investor materials provide supporting detail and guidance context — investors had concrete slides and call access to validate the beat. Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results
• Positive Sentiment: Management commentary/transcripts emphasize robust demand and product momentum (useful for gauging sustainability of growth). DexCom (DXCM) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts remain generally bullish — coverage pieces on target prices keep upside expectations in the market narrative, but targets vary and will influence trading as updates arrive. What Are Wall Street Analysts’ Target Price for DexCom Stock?
• Neutral Sentiment: New product/engagement initiative: a Stelo AI upgrade aims to deepen consumer metabolic-health engagement — potentially expands TAM and recurring revenue if adoption follows. DexCom Stelo AI Upgrade Aims To Deepen Consumer Metabolic Health Engagement
• Neutral Sentiment: Press and transcript coverage (Seeking Alpha, Zacks, Benzinga, SFGATE) provide overlapping recaps — useful for detail but largely reiterate the beat rather than new catalysts. DexCom: Q4 Earnings Snapshot
• Negative Sentiment: Technical/valuation headwinds: DXCM trades below its 50- and 200-day moving averages and carries a relatively high PE (~36x), which could limit near-term upside despite the beat. (Background market data: market cap ~$25.4B, P/E-G ~1.22.)
• Negative Sentiment: Short-interest reporting appears inconsistent (entries showing 0 shares), suggesting noisy/uncertain data on positioning — could add volatility if corrected or if short activity actually rises.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.